MX358726B - Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. - Google Patents
Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.Info
- Publication number
- MX358726B MX358726B MX2013015146A MX2013015146A MX358726B MX 358726 B MX358726 B MX 358726B MX 2013015146 A MX2013015146 A MX 2013015146A MX 2013015146 A MX2013015146 A MX 2013015146A MX 358726 B MX358726 B MX 358726B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cell carcinoma
- renal cell
- survival
- predictive biomarker
- Prior art date
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 title abstract 2
- 239000000092 prognostic biomarker Substances 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502686P | 2011-06-29 | 2011-06-29 | |
| PCT/US2012/044673 WO2013003606A1 (en) | 2011-06-29 | 2012-06-28 | Predictive biomarker of survival in the treatment of renal cell carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013015146A MX2013015146A (es) | 2014-03-27 |
| MX358726B true MX358726B (es) | 2018-09-03 |
Family
ID=46545468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013015146A MX358726B (es) | 2011-06-29 | 2012-06-28 | Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9151761B2 (enExample) |
| EP (1) | EP2726088B1 (enExample) |
| JP (1) | JP6069312B2 (enExample) |
| AU (1) | AU2012275346B2 (enExample) |
| CA (1) | CA2840212A1 (enExample) |
| MX (1) | MX358726B (enExample) |
| WO (1) | WO2013003606A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| SG11201703428SA (en) | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Bispecific antibodies and methods of use in ophthalmology |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| CA2963606A1 (en) * | 2014-11-10 | 2016-05-19 | F.Hoffmann-La Roche Ag | Anti-ang2 antibodies and methods of use |
| WO2016209972A1 (en) * | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| JP6853789B2 (ja) * | 2015-12-24 | 2021-03-31 | 公益財団法人がん研究会 | マルチキナーゼ阻害剤の有効性と安全性を予測する検査方法、検査キット、及びバイオマーカー |
| CN108496084B (zh) * | 2016-01-25 | 2021-11-05 | 赛诺菲 | 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US5871723A (en) | 1995-06-06 | 1999-02-16 | The Regent Of The University Of Michigan | CXC chemokines as regulators of angiogenesis |
| US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| JP5179373B2 (ja) * | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−２アンタゴニストとＶＥＧＦ−Ａ、ＫＤＲ、及び／又はＦｌｔ１アンタゴニストの組合せ |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| KR20120043028A (ko) | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| WO2008115714A2 (en) * | 2007-03-20 | 2008-09-25 | Apocell, Inc. | Evaluating rtk target drugs |
| JP5699075B2 (ja) * | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ |
-
2012
- 2012-06-28 JP JP2014519031A patent/JP6069312B2/ja active Active
- 2012-06-28 AU AU2012275346A patent/AU2012275346B2/en active Active
- 2012-06-28 MX MX2013015146A patent/MX358726B/es active IP Right Grant
- 2012-06-28 EP EP12737394.2A patent/EP2726088B1/en active Active
- 2012-06-28 US US14/127,157 patent/US9151761B2/en active Active
- 2012-06-28 CA CA2840212A patent/CA2840212A1/en not_active Abandoned
- 2012-06-28 WO PCT/US2012/044673 patent/WO2013003606A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP6069312B2 (ja) | 2017-02-01 |
| AU2012275346B2 (en) | 2016-03-17 |
| CA2840212A1 (en) | 2013-01-03 |
| EP2726088A1 (en) | 2014-05-07 |
| EP2726088B1 (en) | 2019-01-02 |
| JP2014521070A (ja) | 2014-08-25 |
| WO2013003606A1 (en) | 2013-01-03 |
| AU2012275346A1 (en) | 2013-12-19 |
| MX2013015146A (es) | 2014-03-27 |
| US9151761B2 (en) | 2015-10-06 |
| US20140348824A1 (en) | 2014-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| TN2013000412A1 (en) | Bcma-based stratification and therapy for multiple myeloma patients | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| MX358726B (es) | Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales. | |
| IL229114A0 (en) | Methods for treating cancer and inflammatory diseases using servalon as a predictor | |
| PT2544680E (pt) | Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| HRP20180959T1 (hr) | Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata | |
| MY161237A (en) | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer | |
| UA123212U (uk) | Спосіб лікування раку молочної залози | |
| ZA201503054B (en) | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors | |
| MX2018011832A (es) | Metodos y composiciones para uso en diagnostico de pacientes con cancer. | |
| IN2014DN06104A (enExample) | ||
| PH12013501894A1 (en) | Human tissue factor antibody and uses thereof | |
| IL230698A0 (en) | Use of preparations containing crizotinib to treat cancer | |
| MY165499A (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| GB201100180D0 (en) | Tumour cell and tissue culture | |
| MX2012002909A (es) | Metodos y composiciones para su uso en diagnostico de pacientes con cancer. | |
| MX367255B (es) | Aminoesteroides para tratamiento de una enfermedad asociada con proteina fosfatasa 1b (ptp1b). | |
| MX2012007898A (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| MX364002B (es) | Compuestos y composiciones activadoras de enzima. | |
| BR112014012495A2 (pt) | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer | |
| IL228579A0 (en) | Methods for predicting and improving the survival of gastric cancer patients | |
| PH12013501163A1 (en) | Compositions comprising a p13k inhibitor and a mek inhibitor and their use for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |